Why Did Immutep’s Loss Double Despite Securing USD 20M Upfront?

• Half-year loss doubles to A$44.9 million driven by increased R&D and clinical expenses
• Strategic collaboration with Dr. Reddy’s Laboratories yields USD 20 million upfront payment
• Pivotal Phase III trial TACTI-004 for non-small cell lung cancer progressing with strong enrolment
• Multiple oncology and autoimmune trials advancing with encouraging data and regulatory feedback